Research ArticleOriginal Article
Open Access

The pattern of gynecological malignancies in Al-Madinah Al-Munawarah region, Saudi Arabia

An overview of 6 years

Nawal H. Almohammadi
Saudi Medical Journal March 2022, 43 (3) 283-290; DOI: https://doi.org/10.15537/smj.2022.43.3.20210888

Article Figures & Data

Figures

Tables

  • Table 1

    - Socio-demographic and clinical characteristics of the studied population.

    Variablesn (%)
    Age, mean±SD (min-max)54.40±16.1 (1-91)
    Total200 (100)
    Year
    201527 (13.5)
    201635 (17.5)
    201735 (17.5)
    201821 (10.5)
    201932 (16.0)
    202031 (15.5)
    202119 (9.5)
    Nationality
    Saudi168 (84.0)
    Non Saudi32 (16.0)
    Age
    ≥30 years19 (9.5)
    31-45 years31 (15.5)
    46-60 years75 (37.5)
    61-75 years60 (30.0)
    >75 years15 (7.5)
    Anatomical site
    Cervix27 (13.5)
    Ovary27 (13.5)
    Uterus138 (69.0)
    Vagina3 (1.5)
    Vulva5 (2.5)
    Pathological grade
    FIGO grade133 (29.5)
    FIGO grade260 (53.6)
    FIGO grade311 (9.8)
    NA8 (7.1)
    Anatomical site of malignancy
    Cervix27 (13.5)
    Ovary27 (13.5)
    Uterus138 (69.0)
    Vagina3 (1.5)
    Vulva5 (2.5)

    SD: standard deviation, FIGO: Federation of Gynecology and Obstetrics NA: not applicable

    • Table 2

      - Correlation of age and anatomical site of the malignancies.

      VariablesTotalAge
      ≥30 years old*31-45 years old*46-60 years old*61-75 years old*>75 years old*Mean±SD†,‡
      Total200 (100)19 (100)31 (100)75 (100)60 (100)15 (100)54.40±16.1
      Anatomical site
      Cervix27 (13.5)1 (5.3)7 (22.6)11 (14.7)5 (8.3)3 (20.0)54.67±13.9*
      Ovary27 (13.5)11 (57.9)10 (32.3)5 (6.7)1 (1.7)0 (0.0)34.89±15.5†
      Uterus138 (69.0)5 (26.3)13 (41.9)58 (77.3)50 (83.3)12 (80.0)58.47±13.1*
      Vagina3 (1.5)2 (10.5)0 (0.0)0 (0.0)1 (1.7)0 (0.0)32.00±31.6†
      Vulva5 (2.5)0 (0.0)1 (3.2)1 (1.3)3 (5.0)0 (0.0)59.40±12.3*

      *Significant using Chi-square test (p≤0.001), †significant using one-way ANOVA test (p≤0.001), ‡post hoc test (least significant difference)

      • Table 3

        - Pathological diagnosis of the patients.

        Pathological diagnosisn (%)
        Tumours of uterine corpus135 (67.5)
        Epithelial tumours117 (86.7)
        Clear cell carcinoma3 (2.6)
        Endometrioid carcinoma106 (90.6)
        Serous carcinoma5 (4.3)
        Small cell neuroendocrine carcinoma1 (0.9)
        Undifferentiated carcinoma2 (1.7)
        Mesenchymal tumours13 (9.6)
        Endometrial stromal sarcoma, high-grade2 (15.4)
        Endometrial stromal sarcoma, low-grade6 (46.2)
        Leiomyosarcoma4 (30.8)
        Undifferentiated sarcoma1 (7.7)
        Mixed epithelial and mesenchymal tumours5 (3.7)
        Carcinosarcoma2 (40.0)
        Mixed cell carcinoma3 (60.0)
        Ovarian neoplasm27 (13.5)
        Epithelial tumours borderline6 (22.2)
        Mucinous borderline tumor with microinvasion2 (33.3)
        Serous borderline tumor2 (33.3)
        Serous borderline tumor, micropapillary variant2 (33.3)
        Epithelial tumours malignant10 (37.0)
        Endometrioid carcinoma1 (10.0)
        Mucinous adenocarcinoma3 (30.0)
        Serous carcinoma6 (60.0)
        Sex-cord tumours6 (22.2)
        Adult granulosa cell tumor5 (83.3)
        Juvenile granulosa tumour1 (16.7)
        Germ cell tumours3 (11.1)
        Dysgerminoma2 (66.7)
        Immature teratoma1 (33.3)
        Plasmacytoma1 (3.7)
        Plasmacytoma1 (100)
        Secondary tumours1 (3.7)
        Metastatic carcinoma1 (100)
        Tumour of uterine cervix27 (13.5)
        Clear cell carcinoma1 (3.7)
        Squamous cell carcinoma24 (88.9)
        Undifferentiated carcinoma2 (7.4)
        Valvar and vaginal tumours8 (4.0)
        Botryoid rhabdomyosarcoma1 (12.5)
        Squamous cell carcinoma7 (87.5)
        Gestational trophoblastic neoplasm3 (1.5)
        Choriocarcinoma1 (33.3)
        Epithelioid trophoblastic tumor1 (33.3)
        Gestational choriocarcinoma1 (33.3)
      • Table 4

        - Female genital malignancies across different age groups.

        VariablesTotalAge*
        ≥30 years old31-45 years old46-60 years old61-75 years old>75 years old
         n (%)
        Total200 (100)19 (100)31 (100)75 (100)60 (100)15 (100)
        Tumours of uterine corpus135 (67.5)3 (15.8)12 (38.7)58 (77.3)50 (83.3)12 (80.0)
        Ovarian neoplasm27 (13.5)11 (57.9)10 (32.3)5 (6.7)1 (1.7)0 (0.0)
        Tumour of uterine cervix27 (13.5)1 (5.3)7 (22.6)11 (14.7)5 (8.3)3 (20.0)
        Valvar and vaginal tumours8 (4.0)2 (10.5)1 (3.2)1 (1.3)4 (6.7)0 (0.0)
        Gestational trophoblastic neoplasm3 (1.5)2 (10.5)1 (3.2)0 (0.0)0 (0.0)0 (0.0)

        *Significant using Chi-square test (p<0.001)

        • Table 5

          - Female genital malignancies across different years.

          VariablesTotalYear
          2015201620172018201920202021
          n (%)
          Total200 (100)27 (100)35 (100)35 (100)21 (100)32 (100)31 (100)19 (100)
          Tumours of uterine corpus135 (67.5)16 (59.3)25 (71.4)18 (51.4)16 (76.2)26 (81.3)21 (67.7)13 (68.4)
          Ovarian neoplasm27 (13.5)5 (18.5)5 (14.3)7 (20.0)1 (4.8)2 (6.3)3 (9.7)4 (21.1)
          Tumour of uterine cervix27 (13.5)6 (22.2)4 (11.4)6 (17.1)3 (14.3)1 (3.1)5 (16.1)2 (10.5)
          Valvar and vaginal tumours8 (4.0)0 (0.0)0 (0.0)3 (8.6)1 (4.8)3 (9.4)1 (3.2)0 (0.0)
          Gestational trophoblastic neoplasm3 (1.5)0 (0.0)1 (2.9)1 (2.9)0 (0.0)0 (0.0)1 (3.2)0 (0.0)
        Back to top

        In this issue

        Print
        Download PDF
        Email Article
        Citation Tools
        Bookmark this article

        Jump to section

        Keywords